Visceral metastases should distinguish between liver or lung when treating HR-positive/HER2-negative advanced breast cancer with fulvestrant
期刊论文会议论文
编号：
f4e0096c-a230-4af5-a78f-e2b98fa5ec98
作者：
He, M.[1]Li, J. J.[1]Zuo, W. J.[1]Wang, Z. H.[1]Shao, Z. M.[1]
语种：
英文
期刊：
BREASTISSN：0960-97762019 年44 卷(S59 - S59) ; MAR
收录：
推荐引用方式 GB/T 7714：
He M.,Li J. -J.,Zuo W. -J., et al. Visceral metastases should distinguish between liver or lung when treating HR-positive/HER2-negative advanced breast cancer with fulvestrant [J].BREAST,2019,44:S59-S59.
APA：
He M.,Li J. -J.,Zuo W. -J.,Wang Z. -H.,&Shao Z. -M..(2019).Visceral metastases should distinguish between liver or lung when treating HR-positive/HER2-negative advanced breast cancer with fulvestrant .BREAST,44:S59-S59.
MLA：
He M., et al. "Visceral metastases should distinguish between liver or lung when treating HR-positive/HER2-negative advanced breast cancer with fulvestrant" .BREAST 44(2019):S59-S59.
(8.0+极速模式)